105P - A literature-based meta-analysis about the comparison between platinum-based doublet and single agent chemotherapy in PS 2 NSCLC patients

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Cancer in Special Situations
Presenter Christian Rolfo
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors C.D. Rolfo1, F. Passiglia1, G. Bronte2, S. Rizzo2, I. Gil Bazo3, E. fiorentino4, J.P. van Meerbeeck5, A. Russo2
  • 1Phase I- Early Clinical Trials Unit, Antwerp University Hospital, 2650 - Edegem/BE
  • 22. department Of Surgical, Oncological And Oral Sciences, Section Of Medical Oncology, Palermo University, 90100 - Palermo/IT
  • 3Medical Oncology, Clinica Universidad de Navarra, 31008 - Pamplorna/ES
  • 4Department Of Surgical, Oncological And Oral Sciences, Section Of Surgical Oncology, Palermo University, 90100 - Palermo/IT
  • 5Thoracic Oncology, Multidisciplinary Oncology Center Antwerp (moca), Antwerp University Hospital, 2650 - Edegem/BE

Abstract

Background: Platinum-based doublet chemotherapy is still the standard 1st-line treatment for most EGFR wild-type NSCLC patients with performance status (PS) 0-1. However the treatment of PS2 patients is still controversial. Single-agent treatment with third-generation agents is recommended as the best option. Recently new prospective, randomized- phase III trials showed very interesting updates regarding the treatment of PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.